BIOLEGEND TOTALSEQ ANTIBODIES FOR SINGLE CELL ASSAYS (AMBIS 2177674)

This is a Notice of Intent, not a request for proposal.  The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Biolegend, Inc., 8999 Biolegend Way, San Diego, CA 92121-3719, USA to procure TOTALSEQ antibodies for single cell assays in cerebrospinal fluid (CSF) using RNA sequencing (scCITEseq) related research.

These items (all of which are antibodies and associated solutions to make the antibodies work in experiments) are used to perform single-cell assays, which allow us to target specific immune cells that we are interested in studying. These antibodies are needed for an on-going project aim to isolate and characterize immune cells present in multiple sclerosis and healthy patients' cerebrospinal fluid (CSF) using RNA sequencing (scCITEseq). This kind of characterization of cells will try to identify cell-specific molecular pathways underlying disease progression.  Only BioLegend can provide oligonucleotide-tagged antibodies compatible with scCITEseq platform.

The main object of this research is to develop and optimize scCITEseq methodology applicable for longitudinal prospective analysis of cell surface markers and scRNAseq of CSF cells in MS and controls. We expect to analyze, in the blinded fashion, up to 100 CSF samples/year, up to 20,000 CSF cells/sample. We also expect that we will need total 200-300 samples to perform training cohort analyses and to validate major findings in the independent validation cohort.

The current requirement is for – PLEASE SEE BILL OF MATERIALS.

The Place of performance is NIH Building 10, 10 Center Drive, Bethesda, MD  20892.

When: upon receipt until reagents are exhausted.

The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-23-2177674) to Rita Davis at rita.davis@nih.gov by 11:00 am eastern standard time, Monday, June 26, 2023.  All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.